NEUROPSYCHOLOGICAL REHABILITATION FOR ALCOHOL USE DISORDERS
NCT06933186, Not applicable, Active not recruiting, University of Lisbon
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | NEUROPSYCHOLOGICAL REHABILITATION FOR ALCOHOL USE DISORDERS | ClinicalTrials.gov |
| NCT number | NCT06933186 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 48 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Lisbon | ClinicalTrials.gov |
| Conditions | Alcohol Use Disorder Cognitive Decline | ClinicalTrials.gov |
| Interventions | Neuropsychological rehabilitation, Weekly therapeutic groups | ClinicalTrials.gov |
| First posted | 2025-04-18 | ClinicalTrials.gov |
| Last updated | 2025-04-18 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Frontal Assessment Battery - FAB (total score) (Lima, Meireles, Fonseca, Castro, Garrett; 2008). | Baseline, one, three and six months | * assessment general executive functioning * divided into six subscales: abstract thinking (test of similarities); mental flexibility (phonemic fluency); motor programming (Luria motor series - fist-edge-palm patterns); sensitivity to interference (antagonistic instructions); inhibitory control (go-no-go) and environment independence (suppression of grasping behavior); * minimum score: 0; maximum score: 18; * a higher score indicates better cognitive function; * cutoff point: ≥14 (without prejudice to function). | ClinicalTrials.gov |
| Secondary | Letter-number sequence subscale of the Wechsler Adult Intelligence Scale - WAIS-III (Weschler et al, 2017) | Baseline, three and six months | * Assessment working memory * higher scores mean better results * the score is standardized considering age and level education. | ClinicalTrials.gov |
| Secondary | Verbal Fluency Test (Cavaco et al, 2013a) | Baseline, three and six months | * assesses the ability to generate words, considering the semantic (Semantic Verbal Fluency) and phonemic (Phonemic Verbal Fluency) categories - only the phonemic category will be used; * The greater the number of words produced, the better the results. * the data is standardized considering age and education | ClinicalTrials.gov |
| Secondary | World Health Organization Quality of Life - BREF - WHOQOL-BREF (WHOQOL Group;1998; Skevington et al, 2004) | Baseline, one, three and six months | * Assessment quality of life; * Organized into four dimensions of quality of life: physical, psychological, social relations and environment; * Calculation of a general quality of life indicator * The score ranges from 0 to 100, with a higher score corresponding to a better perception of quality of life | ClinicalTrials.gov |
| Secondary | Trail Making Test - TMT (Cavaco et al, 2013) | Baseline, three and six months | * Assesses cognitive flexibility; * Consists of two parts (A and B); only part B will be used in this investigation. * Time (in seconds) is counted, which the criterion is for scoring the test; * The longer the execution time, the worse the results * The data is standardized considering age and education | ClinicalTrials.gov |
| Secondary | Stroop Color and Word Test (Fernandes, 2013) | Baseline, three and six months | * Assessment inhibition; * The quote corresponds to the number of elements performed within a 45-second interval, and Interference is also calculated. * Normative performance corresponds to one standard deviation of the population mean. | ClinicalTrials.gov |
| Other | Severity of Alcohol Dependence Questionnaire -SADQ (Breda et al., 2018) | one, three and six months | * Assesses the degree of alcohol dependence; * obtains a severity index that varies between \>16 points - mild dependence; 16-30 - moderate dependence and \<31 - severe dependence. | ClinicalTrials.gov |
| Other | Hospital Anxiety and Depression Scale- HADS (McIntyre et al, 1999) | one, three and six months | * Assesses emotional aspects (anxiety and depression); * -Minimum score: 0; maximum score: 21; * Higher values indicate higher levels of anxiety and depression; * Anxiety and depression can be classified as "normal" (0-7), mild (8-10), moderate (11-15) and severe (16-21) | ClinicalTrials.gov |
| Other | Montreal Cognitive Assessment - MOCA (Simões, Freitas, Santana, Firmino, Martins, Nasreddine, Vilar; 2008) | one moth | * Global cognitive assessment, grouped into the following dimensions: short-term memory, executive functions, visuospatial capacity, language, attention, concentration and working memory and temporal and spatial orientation; * Cutoff point: ≥ 26; means cognitive deterioration. | ClinicalTrials.gov |
| Other | Sociodemographic questionnaire | Baseline, one, three and six months | Sociodemographic characterization of the sample | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Go/No-Go Task | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)